Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Research Article
4 July 2024

Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims

Authors: Cong Zhu, Craig Zaidman, Bora Youn, Angela D Paradis, Stephanie Raynaud, Bridget A Neville, and Nicole B Johnson [email protected]Author Info & Affiliations
Volume 13, Number 7
https://doi.org/10.57264/cer-2023-0187
PDFFormats

Abstract

Aim: Nusinersen, administered by intrathecal injection at a dose of 12 mg, is indicated across all ages for the treatment of spinal muscular atrophy (SMA). Evidence on real-world healthcare resource use (HRU) and costs among patients taking nusinersen remains limited. This study aimed to evaluate real-world HRU and costs associated with nusinersen use through US claims databases. Patients & methods: Using the Merative™ MarketScan® Research Databases, patients with SMA receiving nusinersen were identified from commercial (January 2017 to June 2020) and Medicaid claims (January 2017 to December 2019). Those likely to have complete information on the date of nusinersen initiation and continuous enrollment 12 months pre- and post-index (first record of nusinersen treatment) were retained. Number and costs (US$ 2020) of inpatient admissions and emergency department (ED) visits, unrelated to nusinersen administration, were evaluated for 12 months pre- and post-nusinersen initiation and stratified by age: pediatric (<18 years) and adult (≥18 years). Results: Overall, 103 individuals treated with nusinersen were retained: 59 were pediatric (mean age [range]: 9 [1–17] years), and 44 were adults (30 [18–63] years). Inpatient admissions decreased by 41% for pediatrics and 67% for adults in the 12 months post-treatment versus the 12 months pre-treatment. Average inpatient admission costs per patient for the pediatric cohort decreased by 63% ($22,903 vs $8466) and by 79% ($13,997 vs $2899) for the adult cohort when comparing the 12 months pre-index with the 12 months post-index period. Total ED visits and ED visit costs decreased by 8% and 35%, respectively, for the overall cohort over the 12-month period pre- and post-index. Conclusion: Using US claims databases, nusinersen treatment in pediatric and adult patients was associated with reductions in HRU and costs over a 12-month period post-treatment initiation relative to the pre-treatment period.

Plain language summary

What is this article about/what is the aim of the research?

Spinal muscular atrophy (SMA) is an inherited disease affecting mainly infants and children, but it can also present in adults. This condition damages nerve cells and muscles that control key activities, such as sitting, walking, speaking, swallowing and breathing. Nusinersen was the first drug approved in the US to help manage SMA. It is administered by injection with a thin needle into a space in the lower back, below the end of the spinal cord, through a medical procedure known as a “lumbar puncture”. There is very little information on the medical management for people with SMA receiving nusinersen. Using insurance claims processed in the US, this study assessed trends in hospital stays, in emergency department (ED) visits and in related medical costs before and after nusinersen use.

What were the results?

Comparing the 12 months before nusinersen treatment with the 12 months following treatment, the number of hospital stays was 41% lower for children and 67% lower for adults after treatment. The average cost per person associated with hospital stays was 63% lower for children and 79% lower for adults. The number of days spent at the hospital was also reduced for all ages following nusinersen treatment. The number of ED visits and the resulting costs were 8% and 35% lower, respectively, for the overall cohort.

What do these results mean?

Overall, nusinersen treatment lessens the burden of disease among people with SMA in the US by lowering the rate of hospital stays and ED visits, and by reducing associated costs.

Supplementary Material

File (supplementary material.docx)

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat. Rev. Dis. Primers 8(1), 52 (2022).
PubMed
Google Scholar
2.
Darras BT, Monani UR, De Vivo DC. Genetic disorders affecting the motor neuron: spinal muscular atrophy. In: Swaiman's Pediatric Neurology (6th Edition). Swaiman KF, Ashwal S, Ferriero DMet al. et al. (Eds). Elsevier, The Netherlands, 1057–1064 (2017).
Google Scholar
3.
Talbot K, Tizzano EF. The clinical landscape for SMA in a new therapeutic era. Gene Ther. 24(9), 529–533 (2017).
PubMed
Google Scholar
4.
Finkel RS, McDermott MP, Kaufmann P et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 83(9), 810–817 (2014).
PubMed
Google Scholar
5.
Hoy SM. Nusinersen: first global approval. Drugs 77(4), 473–479 (2017).
PubMed
Google Scholar
6.
Parente V, Corti S. Advances in spinal muscular atrophy therapeutics. Ther. Adv. Neurol. Disord. 11, 1756285618754501 (2018).
Google Scholar
7.
Food and Drug Administration. Spinraza prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209531s011lbl.pdf (Accessed: 8 August 2023).
Google Scholar
8.
European Medicines Agency. Spinraza summary of product characteristics. Available at: https://www.medicines.org.uk/emc/product/2715/smpc (Accessed: 8 August 2023).
Google Scholar
9.
Chiriboga CA, Swoboda KJ, Darras BT et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 86(10), 890–897 (2016).
PubMed
Google Scholar
10.
Finkel RS, Chiriboga CA, Vajsar J et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a Phase II, open-label, dose-escalation study. Lancet 388(10063), 3017–3026 (2016).
PubMed
Google Scholar
11.
Finkel RS, Mercuri E, Darras BT et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377(18), 1723–1732 (2017).
PubMed
Google Scholar
12.
De Vivo DC, Bertini E, Swoboda KJ et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase II NURTURE study. Neuromuscul. Disord. 29(11), 842–856 (2019).
PubMed
Google Scholar
13.
Hagenacker T, Wurster CD, Gunther R et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 19(4), 317–325 (2020).
PubMed
Google Scholar
14.
Mercuri E, Darras BT, Chiriboga CA et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N. Engl. J. Med. 378(7), 625–635 (2018).
PubMed
Google Scholar
15.
Crawford TO, Swoboda KJ, De Vivo DC et al. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve 68(2), 157–170 (2023).
PubMed
Google Scholar
16.
Darras BT, Chiriboga CA, Iannaccone ST et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1/2 studies. Neurology 92(21), e2492–e2506 (2019).
PubMed
Google Scholar
17.
Maggi L, Bello L, Bonanno S et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J. Neurol. Neurosurg. Psychiatry 91(11), 1166–1174 (2020).
PubMed
Google Scholar
18.
Coratti G, Cutrona C, Pera MC et al. Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet J. Rare Dis. 16(1), 430 (2021).
PubMed
Google Scholar
19.
Duong T, Wolford C, McDermott MP et al. Nusinersen treatment in adults with spinal muscular atrophy. Neurol. Clin. Pract. 11(3), e317–e327 (2021).
PubMed
Google Scholar
20.
Elsheikh B, Severyn S, Zhao S et al. Safety, tolerability, and effect of nusinersen treatment in ambulatory adults with 5q-SMA. Front. Neurol. 12, 650535 (2021).
PubMed
Google Scholar
21.
Elsheikh B, Severyn S, Zhao S et al. Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy. Front. Neurol. 12, 650532 (2021).
PubMed
Google Scholar
22.
Armstrong EP, Malone DC, Yeh WS, Dahl GJ, Lee RL, Sicignano N. The economic burden of spinal muscular atrophy. J. Med. Econ. 19(8), 822–826 (2016).
PubMed
Google Scholar
• Patients with SMA were found to have significantly higher hospitalizations and medical costs than matched comparators using a retrospective study design of administrative claims data in the US.
23.
Tan H, Gu T, Chen E, Punekar R, Shieh PB. Healthcare utilization, costs of care, and mortality among patients with spinal muscular atrophy. J. Health Econ. Outcomes Res. 6(3), 185–195 (2019).
Google Scholar
• Relative to the general population, healthcare utilization and costs were higher for SMA patients in the US using a retrospective cohort study design of administrative claims.
24.
Belter L, Cruz R, Kulas S, McGinnis E, Dabbous O, Jarecki J. Economic burden of spinal muscular atrophy: an analysis of claims data. J. Mark Access Health Policy 8(1), 1843277 (2020).
PubMed
Google Scholar
• Direct inpatient and outpatient costs for untreated SMA patients was significantly higher relative to the general population in the US using administrative claims data.
25.
Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. J. Med. Econ. 23(1), 70–79 (2020).
PubMed
Google Scholar
•• Study showed nusinersen had fewer inpatient stays and lower inpatient costs when compared with similarly aged (<2 years) untreated patients with SMA in the US using administrative claims data.
26.
Lee M Jr, Franca UL, Graham RJ, McManus ML. Pre-nusinersen hospitalization costs of children with spinal muscular atrophy. Pediatr. Neurol. 92, 3–5 (2019).
PubMed
Google Scholar
27.
Menard J, Seferian AM, Fleurence E et al. Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen. Pediatr. Pulmonol. 57(6), 1505–1512 (2022).
PubMed
Google Scholar
•• This retrospective multicenter study in France found a significant decrease in total number of inpatient admissions between the first and second year in SMA patients treated with nusinersen with SMA Type I.
28.
Chen KA, Widger J, Teng A, Fitzgerald DA, D'Silva A, Farrar M. Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-year single centre Australian experience. Paediatr. Respir. Rev. 39, 54–60 (2021).
PubMed
Google Scholar
•• This single center observational cohort study of patients with SMA Type I treated with nusinersen in Australia found the total number of hospitalizations was 50% lower in the second year of nusinersen treatment relative to the first year.
29.
Merative. Merative Marketscan Research Databases Explainer. Available at: https://www.merative.com/content/dam/merative/documents/brief/marketscan-explainer-general.pdf (Accessed: 28 November 2023).
Google Scholar
30.
Youn B, Proud CM, Wang N et al. Examining real-world adherence to nusinersen for the treatment of spinal muscular atrophy using two large US data sources. Adv. Ther. 40(3), 1129–1140 (2023).
PubMed
Google Scholar
• This analysis highlighted important study methodology and inclusion/exclusion criteria when using real-world administrative databases in the US for evaluation of nusinersen treatment patterns.
31.
Johnson NB, Proud C, Wassel CL, Dreyfus J, Cochrane T, Paradis AD. Characterization of adult patients with SMA treated in US hospital settings: a natural history study in the premier healthcare database. J Neuromuscul Dis. 8(4), 569–578 (2021).
PubMed
Google Scholar
• This publication previously evaluated and characterized common comorbidities related to SMA disease using real-world administrative claims data and codes in the US.
32.
Finkel RS, Mercuri E, Meyer OH et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul. Disord. 28(3), 197–207 (2018).
PubMed
Google Scholar
33.
Sansone VA, Pirola A, Albamonte E et al. Respiratory needs in patients with Type 1 spinal muscular atrophy treated with nusinersen. J. Pediatr. 219, 223–228.e4 (2020).
PubMed
Google Scholar
|